Umeå University's logo

umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
A comparison of different definitions of growth response in short prepubertal children treated with growth hormone
Department of Women’s and Children’s Health, Karolinska Institute and University Hospital, Stockholm, Sweden.
Department of Clinical Medicine, Section for Pediatrics, University of Bergen, Norway.
Department of Pediatrics, Sahlgrenska Academy, University of Gothenburg, Sweden.
Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland.
Show others and affiliations
2011 (English)In: Hormone research in paediatrics, ISSN 1663-2826, Vol. 75, no 5, p. 335-345Article in journal (Refereed) Published
Abstract [en]

Background: How to define poor growth response in the management of short growth hormone (GH)-treated children is controversial.

Aim: Assess various criteria of poor response.

Subjects and Methods: Short GH-treated prepubertal children [n = 456; height (Ht) SD score (SDS) ≤-2] with idiopathic GH deficiency (IGHD, n = 173), idiopathic short stature (ISS, n = 37), small for gestational age (SGA, n = 54), organic GHD (OGHD, n = 40), Turner syndrome (TS, n = 43), skeletal dysplasia (n = 15), other diseases (n = 46) or syndromes (n = 48) were evaluated in this retrospective multicenter study. Median age at GH start was 6.3 years and Ht SDS -3.2.

Results: Median [25-75 percentile] first-year gain in Ht SDS was 0.65 (0.40-0.90) and height velocity (HtV) 8.67 (7.51-9.90) cm/year. Almost 50% of IGHD children fulfilled at least one criterion for poor responders. In 28% of IGHD children, Ht SDS gain was <0.5 and they had lower increases in median IGF-I SDS than those with Ht SDS >0.5. Only IGHD patients with peak stimulated growth hormone level <3 μg/l responded better than those with ISS. A higher proportion of children with TS, skeletal dysplasia or born SGA had Ht SDS gain <0.5.

Conclusion: Many children respond poorly to GH therapy. Recommendations defining a criterion may help in managing short stature patients.

Place, publisher, year, edition, pages
2011. Vol. 75, no 5, p. 335-345
Keywords [en]
Growth hormone therapy, Growth response, Height velocity, Growth hormone deficiency, Organic growth hormone deficiency, Small for gestational age, Idiopathic short stature, Turner syndrome, Skeletal dysplasia, Growth prediction
National Category
Endocrinology and Diabetes Pediatrics
Identifiers
URN: urn:nbn:se:umu:diva-39706DOI: 10.1159/000322878PubMedID: 21228552Scopus ID: 2-s2.0-79955692977OAI: oai:DiVA.org:umu-39706DiVA, id: diva2:395178
Available from: 2011-02-04 Created: 2011-02-04 Last updated: 2023-03-24Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Kriström, Berit

Search in DiVA

By author/editor
Kriström, Berit
By organisation
Paediatrics
Endocrinology and DiabetesPediatrics

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 468 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf